{"url_path":"/sec/nthi/8-k/2026-07-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1979414/0001829126-26-007585-index.html","accession_number":"0001829126-26-007585","cik":"0001979414","ticker":"NTHI","issuer_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1979414/0001829126-26-007585-index.html","primary_entity_key":"0001979414","primary_entity_name":"NEONC TECHNOLOGIES HOLDINGS, INC."},"word_count":144,"has_tables":true,"body_markdown":"** **\n\n**Item 7.01.**\n**Regulation FD Disclosure.**\n\n \n\nOn July 15, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing and controls development program for NEO212, the Company’s novel temozolomide-perillyl alcohol conjugate. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\n*The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.*"}